Companies ›Healthcare ›SKYE.O

SKYE.O — NASDAQ Biotechnology & Medical Research

Skye Bioscience Inc

$0,58

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

20,4M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

-6,4 %

Net margin

—

Debt / equity

0,06

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,85

Open

—

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Skye Bioscience Inc is a biotechnology company focused on the development of novel therapeutics for the treatment of autoimmune and inflammatory diseases, primarily through its lead product candidate, SKY5988, which is in clinical trials for the treatment of atopic dermatitis.

Business. Skye Bioscience Inc (SKYE.O) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. No specific operating segments or geographic revenue breakdowns are provided in the available data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

Generated · model-assisted

Sell-side consensus

BUY8 analysts

7 buy1 hold0 sell

Avg 12m price target7,71

Analyst recommendations

8 analysts · consensus Buy

Buy7

Hold1

Sell0

12-month price target

7,71

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

8 analysts · indicative

Ownership→

BlackRock Institutional Trust Company, N.A.

largest disclosed fund holder

Profitability→

-6,4 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning SKYE.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to SKYE.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Skye Bioscience Inc (SKYE.O) is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. No specific operating segments or geographic revenue breakdowns are provided in the available data.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityHealthcare Diagnostics

AI synthesis

GENERATED

Skye Bioscience Inc maintains a strong liquidity position, with cash and equivalents amounting to $83.34 million, significantly exceeding its total liabilities of $15.95 million, resulting in a current ratio of 5.99. The company's price-to-book ratio of 0.39 indicates that the market values the company at a discount to its book value, which may reflect the high-risk nature of its development-stage operations.

The company's profitability metrics are negative, with a return on equity of -6.36% and a return on assets of -5.29%, indicating that it is not generating returns for shareholders or asset holders. These figures are in line with the typical performance of early-stage biotechnology firms, which often prioritize research and development over profitability.

Skye Bioscience Inc does not disclose specific revenue by segment or geographic region, but as a development-stage company, its operations are likely concentrated in the United States, where it is headquartered. The lack of geographic diversification could pose a risk if regulatory or market conditions in the U.S. change unfavorably.

The company's growth trajectory is speculative, as it has not yet generated revenue from product sales. Analysts have provided a wide range of price targets, from $2.00 to $20.00, with a mean of $7.71 and a median of $6.00, suggesting significant uncertainty about its future performance. The mean recommendation of 1.88 indicates a generally positive outlook, with 2 strong buy and 5 buy ratings.

Skye Bioscience Inc faces low immediate liquidity and dilution risks, as no filing-based flags were detected. However, the company's negative operating and net income, combined with negative operating and free cash flows, suggests that it will need to secure additional financing to fund its operations and clinical trials. The low dilution risk is somewhat mitigated by the fact that the company has not issued additional shares recently.

Recent events include the ongoing clinical trials for SKY5988, which is the company's lead product candidate. The company has also received a mean price target of $7.71 from analysts, indicating a generally positive sentiment despite the high variability in individual estimates.

Key takeaways

Skye Bioscience Inc has a strong liquidity position with $83.34 million in cash and equivalents.
The company is not currently profitable, with a return on equity of -6.36% and a return on assets of -5.29%.
The company's operations are likely concentrated in the United States, with no disclosed geographic diversification.
Analysts have provided a wide range of price targets, from $2.00 to $20.00, with a mean of $7.71 and a median of $6.00.
The company faces low immediate liquidity and dilution risks but will need additional financing to fund its operations and clinical trials.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Quarterly

Annual

QUARTERLYFiled 2026-03-10

Q4 2025 · Quarter highlights

Open report →

Operating income −39,6% YoY; Net income −48,2% YoY.

Revenue—

Operating income-$14.9M−39,6 % YoY

Net income-$14.4M−48,2 % YoY

Free cash flow-$14.3M−48,2 % YoY

EPS—

Operating cash flow-$43.1M−70,6 % YoY

Financials

Income statement

Revenue—

Gross profit—

Operating income-$14.9M

Net income-$14.4M

Balance sheet

Total assets$28.3M

Total liabilities$8.3M

Total equity$20.0M

Cash & equivalents$5.9M

Long-term debt$0.00

Cash flow

Operating cash flow-$43.1M

CapEx-$6.3k

Free cash flow-$14.3M

SBC—

Highlights

▍Operating income −39,6% YoY
▍Net income −48,2% YoY
▍Free cash flow −48,2% YoY

Valuation TTM

Market price

$0,58

Market cap

$30.6M

Enterprise valueⓘ

-$48.1M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

0.4x

P / Tangible bookⓘ

0.4x

Tangible book

$78.9M

Net cashⓘ

$78.7M

Current ratioⓘ

6.0

Debt / equityⓘ

0.1

ROAⓘ

-5.3%

ROEⓘ

-6.4%

Cash conversionⓘ

94.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

Business relationships9 disclosed relationships · 3 types · extracted from filings & disclosures

Suppliers1

Halozyme Therapeutics IncHALO.OSupplier100%Source ↗

Partners4

Halozyme Therapeutics IncHALO.OPartner100%Source ↗

ELI LILLY AND COMPANYLLY.NPartner95%Source ↗

Structure Therapeutics IncGPCR.OPartner90%Source ↗

Viking Therapeutics IncVKTX.OPartner90%Source ↗

Subsidiaries4

EX21:2f09ffdf2be9EX21:2f09ffdf2be9Subsidiarie97%

EX21:8a7c59ca4292EX21:8a7c59ca4292Subsidiarie97%

EX21:c1899f9fc546EX21:c1899f9fc546Subsidiarie97%

EX21:d092a9a877e8EX21:d092a9a877e8Subsidiarie97%

Supply chain

Vendors → SKYE ↔ Partners → Customers · click any node to drill

5 mentions in 10-K0 from corporate websites0 from news dispatches

Updated 2026-06-24

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,96

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

revision ratio 0,00 · as of 2026-05-17 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,96
Revenue	—no estimate	—no estimate	0 USD
Operating income	—no estimate	—no estimate	-46,4M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution8 analysts

Strong buy2

Buy5

Hold1

Sell0

Strong sell0

12-month price target$7,71 · Median $6,00

Low $2,00High $20,00

Operating income · consensus-46,4M USD

EPS surprise

−46,9 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$2,00

Mean$7,71

Median$6,00

High$20,00

Spot$0,58

+1226.8 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

ROE-6,4 %Above median

D/E0,06Below median

Cash Conv0,94Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 1 355 000 sh35 grants10 insiders

DHILLON PUNITDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 9 013 @ $0,61grant · 2026-03-31
DHILLON PUNITDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 125 000 @ $14,56disposition · 2026-03-31
DHILLON PUNITDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 21 586 @ $3,50disposition · 2026-03-31
DHILLON PUNITDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockDisposed 9 013 @ $3,50disposition · 2026-03-31
DHILLON PUNITDirector, Chief Executive Officer · Stock Option (Right to Buy) → Common StockAcquired 21 586 @ $0,61grant · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 12 000 @ $4,25disposition · 2026-03-31
Smith Karen L.Director · Stock Option (Right to Buy) → Common StockAcquired 75 000 @ $0,61grant · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 17 004 @ $0,61grant · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 17 004 @ $3,50disposition · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 75 000 @ $0,61grant · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 75 000 @ $14,56disposition · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 7 100 @ $0,61grant · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 7 100 @ $3,50disposition · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 200 000 @ $0,61grant · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 200 000 @ $5,15disposition · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 150 000 @ $0,61grant · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockDisposed 150 000 @ $2,89disposition · 2026-03-31
Twitty ChristopherChief Scientific Officer · Stock Option (Right to Buy) → Common StockAcquired 12 000 @ $0,61grant · 2026-03-31
Jenkins AnnalisaDirector · Stock Option (Right to Buy) → Common StockAcquired 75 000 @ $0,61grant · 2026-03-31
Charych Deborah H.Director · Stock Option (Right to Buy) → Common StockAcquired 75 000 @ $0,61grant · 2026-03-31
Grayson Paul A.Director · Stock Option (Right to Buy) → Common StockAcquired 75 000 @ $0,61grant · 2026-03-31
Schwab Andrew J.Director · Stock Option (Right to Buy) → Common StockAcquired 75 000 @ $0,61grant · 2026-03-31
Diep Tuan TuChief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 150 000 @ $0,61grant · 2026-03-31
Diep Tuan TuChief Operating Officer · Stock Option (Right to Buy) → Common StockDisposed 150 000 @ $2,89disposition · 2026-03-31
Diep Tuan TuChief Operating Officer · Stock Option (Right to Buy) → Common StockAcquired 9 194 @ $0,61grant · 2026-03-31

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt

Source documents

Skye Bioscience Inc Market data — financials · 2026-05-29
Skye Bioscience Inc Market data — analyst estimates · 2026-05-29
Skye Bioscience Inc Market data — ESG · 2026-05-29

Ownership & reference

Top holders

BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$9M
Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

Leadership

Punit S. DhillonPresident, Chief Executive Officer, Director

Insider activity

Net selling0 buys · 8 sellsnet -$1,6M2 insiders · last 365d

Schwab Andrew J.Director, 10% owner · Common StockSold 163 979 @ $3,42$561K · 2025-08-22
Schwab Andrew J.Director, 10% owner · Common StockSold 6 470 @ $3,42$22K · 2025-08-22
5AM Partners VII, LLC10% owner · Common StockSold 163 979 @ $3,42$561K · 2025-08-22
5AM Partners VII, LLC10% owner · Common StockSold 6 470 @ $3,42$22K · 2025-08-22
Schwab Andrew J.Director, 10% owner · Common StockSold 58 642 @ $3,57$209K · 2025-08-21
Schwab Andrew J.Director, 10% owner · Common StockSold 2 314 @ $3,57$8K · 2025-08-21
5AM Partners VII, LLC10% owner · Common StockSold 2 314 @ $3,57$8K · 2025-08-21
5AM Partners VII, LLC10% owner · Common StockSold 58 642 @ $3,57$209K · 2025-08-21

Short positioning

1.1Mshares short+10.9% vs prior

7.97days to cover

59.7%short of daily vol

5.6Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

SKYE.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Relationship graph

This companySectorSuppliersPartnersSubsidiaries

Evidence & claims

From filings & derived data

Total assets (YoY) (2025-12-31 vs 2024-12-31): -61.1%Derived (calculated)
Return on assets (FY 2025-12-31): -197.5%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -70.6%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -92.6%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -70.6%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -110.5%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -93.2%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -93.2%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -91.4%Derived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): -99.6%Derived (calculated)
Debt-to-equity (FY 2025-12-31): 0.41xDerived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 79.7%Derived (calculated)
Current ratio (FY 2025-12-31): 3.30xDerived (calculated)
Return on equity (FY 2025-12-31): -279.3%Derived (calculated)
Pre-tax income (annual): USD -55.92MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
Total operating expenses (annual): USD 58.16MSEC XBRL filing
Total liabilities (annual): USD 8.29MSEC XBRL filing
Cash & equivalents (annual): USD 5.88MSEC XBRL filing
Capex (annual): USD 6.31KSEC XBRL filing
Interest expense (annual): USD 0SEC XBRL filing
Operating income (annual): USD -58.16MSEC XBRL filing
Net income (annual): USD -55.92MSEC XBRL filing
Current liabilities (annual): USD 8.21MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-07-29 22:34 UTCEVENTHa Price Listing SKYE remains DEFICIENT (NASDAQ) — cure period. closed below $1.00 for 33 consecutive trading days (last close $0.7872). cure deadline 2027-01-17 (172 days remaining).

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-05-29FILING8-K filing →

2026-05-15FILING8-K filing →

2026-05-11FILING10-Q filing →

2026-04-16FILINGDEF 14A filing →

2026-04-03FILING8-K filing →

2026-03-31 00:00 UTCINSIDER45 insider transactions — 2026-03 45 derivative

2026-03-31INSIDERDiep Tuan Tu acquired 22.0k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu disposed of 9.2k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu disposed of 22.0k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu acquired 125.0k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu disposed of 125.0k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu acquired 8.0k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu disposed of 8.0k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu acquired 7.1k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu disposed of 7.1k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu acquired 75.0k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDiep Tuan Tu disposed of 75.0k sh Stock Option (Right to Buy) — Chief Operating Officer

2026-03-31INSIDERDHILLON PUNIT acquired 250.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-03-31INSIDERDHILLON PUNIT disposed of 250.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-03-31INSIDERDHILLON PUNIT acquired 36.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-03-31INSIDERDHILLON PUNIT disposed of 36.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-03-31INSIDERDHILLON PUNIT acquired 12.4k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-03-31INSIDERDHILLON PUNIT disposed of 12.4k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-03-31INSIDERDHILLON PUNIT acquired 650.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-03-31INSIDERDHILLON PUNIT disposed of 650.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-03-31INSIDERDHILLON PUNIT acquired 125.0k sh Stock Option (Right to Buy) — Director, Chief Executive Officer

2026-03-31INSIDERTwitty Christopher disposed of 17.0k sh Stock Option (Right to Buy) — Chief Scientific Officer

2026-03-31INSIDERTwitty Christopher disposed of 75.0k sh Stock Option (Right to Buy) — Chief Scientific Officer

2026-03-31INSIDERTwitty Christopher acquired 75.0k sh Stock Option (Right to Buy) — Chief Scientific Officer

2026-03-31INSIDERTwitty Christopher acquired 7.1k sh Stock Option (Right to Buy) — Chief Scientific Officer

2026-03-31INSIDERTwitty Christopher disposed of 7.1k sh Stock Option (Right to Buy) — Chief Scientific Officer

2026-03-19FILING8-K filing →

2026-03-10 16:01 UTCEARNINGSQuarterly results — Q4 2025 Net USD -14.4M

2026-03-10 16:01 UTCEARNINGSAnnual results — FY 2026 Net USD -55.9M

2026-03-10FILING8-K filing →

2026-03-10FILING10-K filing →

2026-02-20FILING8-K filing →

Showing the 40 most recent of 63 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation TTM

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread